Details for Patent: 7,320,976

Which drugs does patent 7,320,976 protect, and when does it expire?

Patent 7,320,976 protects COMBIGAN and is included in one NDA.

This patent has twenty-nine patent family members in nineteen countries.

Summary for Patent: 7,320,976

Title:	Combination of brimonidine and timolol for topical ophthalmic use
Abstract:	Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s):	Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	10/685,941
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,320,976
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,320,976

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	COMBIGAN	brimonidine tartrate; timolol maleate	SOLUTION/DROPS;OPHTHALMIC	021398-001	Oct 30, 2007	AB	RX	Yes	Yes						REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY

International Family Members for US Patent 7,320,976

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003228480
Brazil	0302584
Canada	2440764